

## Company Update

Cannatrek is pleased to announce that our first medicinal cannabis seeds ‘Lot 1’ were planted at the UL01 cultivation facility in late August and are now established plants. We look forward to identifying the cannabinoid profile of this inaugural batch when the grow cycle is complete. Attached are some photos of progress made thus far.

Lot 1 is part of a series of breeding harvests, taking place under Cannatrek’s research licence and permit, to establish a cannabinoid library of genetics. This library will be used to provide stable mother stock, supporting commercial medicinal cannabis production. We await two further seed lots, from our partners, which will provide Cannatrek with a full spectrum of genetics to market.



The Courier Mail - Business Section - 06 September 2019

Cannatrek would also like to welcome Dr Susan Pond who has recently joined the Cannatrek board as a non-executive Director. Susan brings decades of experience as a senior leader in business & academia and is recognised for her national & international contributions in medicine, science & technology.

Susan has served on many significant Australian boards, including as CEO and Director of Johnson & Johnson Research, and non-executive director of ANSTO and the Academy of Technology and Engineering. She was chair of AusBiotech Ltd and of several committees for the Australia’s Therapeutic Goods Administration including the Australian Drug Evaluation Committee. Currently, Susan is non-executive Director of two ASX listed biotech companies.

As the Cannatrek greenhouse team tends to our first seeds this Spring, we would also like to acknowledge our dedicated medical access support team for helping doctors and patients access over **1,000 units of Cannatrek’s** low cost medicinal cannabis products.

We look forward to sharing further updates on our trek as we grow.

### TEAM CANNATREK

[www.cannatrek.com](http://www.cannatrek.com)

[investors@cannatrek.com](mailto:investors@cannatrek.com)